BioAtla And GATC Health Announce $40M Special Purpose Vehicle Transaction, With $5M Initial Closing And Remaining $35M Expected In Q1 2026, To Fund Phase 3 Ozuriftamab Vedotin Registrational Trial In 2L+ OPSCC

Benzinga·12/31/2025 12:03:53

语音播报

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.
BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.
Oz-V targets ROR2, an important receptor that not only drives tumor progression, but also regulates cellular senescence, which is linked to chronic diseases associated with aging.